Related Experiment Video
Updated: Oct 9, 2025
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Is 6-Shogaol an Effective Phytochemical for Patients With Lower-risk Myelodysplastic Syndrome? A Narrative Review
Soo Liang Ooi1, Ron Campbell1,2, Sok Cheon Pak1
1Charles Sturt University, Bathurst, NSW, Australia.
Abstract:
Myelodysplastic syndrome (MDS) evolves due to genomic instability, dysregulated signaling pathways, and overproduction of inflammatory markers. Reactive oxygen species contribute to the inflammatory response, which causes gene damage, cellular remodeling, and fibrosis. MDS can be a debilitating condition, and management options in patients with MDS aim to improve cytopenias, delay disease progression, and enhance quality of life. High serum ferritin levels, a source of iron for reactive oxygen species production, correlate with a higher risk of progression to acute myeloid leukemia, and iron overload is compounded by blood transfusions given to improve anemia. 6-shogaol is a natural phenolic compound formed when ginger is exposed to heat and/or acidic conditions, and it has been shown to possess anti-tumor activity against leukemia cell lines and antioxidant effects. This narrative review assessed the potential benefits of this phytochemical in lower-risk MDS patients through examining the current evidence on the pharmacological and therapeutic properties of ginger and 6-shogaol.
Insights
6-shogaol, a compound from ginger, may benefit myelodysplastic syndrome (MDS) patients by reducing inflammation and oxidative stress. This review explores its potential in managing lower-risk MDS.
Area of Science:
- Biochemistry
- Pharmacology
- Oncology
Background:
- Myelodysplastic syndrome (MDS) involves genomic instability, inflammation, and reactive oxygen species (ROS).
- High ferritin levels and iron overload in MDS patients exacerbate ROS production and disease progression.
- Current MDS management focuses on cytopenias, disease delay, and quality of life.
Purpose of the Study:
- To review the potential therapeutic benefits of 6-shogaol for lower-risk myelodysplastic syndrome (MDS).
- To examine the antioxidant and anti-tumor properties of ginger and its compound 6-shogaol.
Main Methods:
- Narrative review of existing scientific literature.
- Analysis of pharmacological and therapeutic data on ginger and 6-shogaol.
- Assessment of evidence related to oxidative stress and inflammation in MDS.
Main Results:
- 6-shogaol exhibits antioxidant and anti-tumor activities relevant to leukemia.
- Ginger compounds, including 6-shogaol, may mitigate ROS-induced damage.
- Iron overload in MDS is linked to increased ROS and disease progression.
Conclusions:
- 6-shogaol presents a potential complementary therapeutic agent for lower-risk MDS.
- Further research is warranted to establish the efficacy and safety of 6-shogaol in MDS patients.
- Targeting oxidative stress and inflammation may be a viable strategy in MDS management.
More Related Videos
09:03Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula
Published on: January 26, 2024
07:40Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023